RDIF, SII to start production of Sputnik V COVID-19 vaccine in India from September \
3 min read
\
\

RDIF, SII to start production of Sputnik V COVID-19 vaccine in India from September

13-Jul-2021
New Delhi [India], July 13 (ANI): The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Serum Institute of India (SII), announced cooperation to produce in India the Russian Sputnik vaccine against coronavirus.
13-Jul-2021 Coronavirus
\
Sputnik V to be produced at SII from September: RDIF \
3 min read
\
\

Sputnik V to be produced at SII from September: RDIF

13-Jul-2021
Moscow [Russia], July 13 (ANI): The first batch of Sputnik vaccine is expected to be produced at Serum Institute of India (SII)'s facilities in September, said Russian Direct Investment Fund (RDIF), the country's sovereign wealth fund on Tuesday.
13-Jul-2021 Coronavirus
\
Sputnik V effective against Delta, other variants of coronavirus, says RDIF study \
4 min read
\
\

Sputnik V effective against Delta, other variants of coronavirus, says RDIF study

12-Jul-2021
New Delhi [India], July 12 (ANI): The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) on Monday announced strong results of the study on neutralizing the activity of sera from individuals vaccinated with Sputnik V vaccine against new variants of SARS-CoV-2.
12-Jul-2021 Coronavirus
\
India’s Morepan Labs manufactures test batch of Russia’s Sputnik V vaccine: RDIF \
2 min read
\
\

India’s Morepan Labs manufactures test batch of Russia’s Sputnik V vaccine: RDIF

06-Jul-2021
Moscow [Russia], July 6 (ANI): Russian Direct Investment Fund (RDIF) and Indian drug firm Morepen Laboratories on Tuesday announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in Himachal Pradesh.
06-Jul-2021 Coronavirus
\
COVID-19 Vaccine: EMA Has Not Raised Any Significant Concerns About Sputnik V Till Now, Says RDIF Chief \
2 min read
\
\

COVID-19 Vaccine: EMA Has Not Raised Any Significant Concerns About Sputnik V Till Now, Says RDIF Chief

04-Jun-2021
The European Medicines Agency (EMA) has so far not raised any crucial issues regarding production and clinical trials of Russia's COVID-19 vaccine Sputnik V, RDIF CEO Kirill Dmitriev said.
04-Jun-2021 Coronavirus
\
Sputnik Light coronavirus vaccine shows 78.6-83.7 pc efficacy among elderly: RDIF \
3 min read
\
\

Sputnik Light coronavirus vaccine shows 78.6-83.7 pc efficacy among elderly: RDIF

02-Jun-2021
Moscow [Russia], June 2 (ANI): The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) on Wednesday announced that the Russian Sputnik Light coronavirus vaccine demonstrates 78.6-83.7 per cent efficacy among the elderly, according to real-world data collected by the Ministry of Health of the Buenos Aires province (Argentina).
02-Jun-2021 Coronavirus
\